Frequently Asked Questions
About Hizentra

What's the difference between intravenous Ig (IVIg) therapy and subcutaneous Ig (SCIg) therapy?

Ig therapy is generally delivered in two basic ways. Intravenous Ig therapy, or IVIg, is administered into the vein by a medical professional about every 3 to 4 weeks.

Subcutaneous Ig therapy, or SCIg, is infused under the skin, using a small needle and an infusion pump. With proper training, most patients can self-infuse SCIg. Most SCIg products are infused once a week, but Hizentra is unique in giving you the option to infuse on a schedule that works for you -- as often as daily or up to once every 2 weeks. Talk with your healthcare provider about the dosing option that's right for you.

After I am trained on self-administration, will I still need to go to my healthcare provider?

Yes. Partnering with one's healthcare provider is necessary for patients with primary immune deficiency disease (PI or PIDD). Regular healthcare provider visits are an important part of your therapy program. At each visit, your healthcare provider will evaluate your dose and your response to treatment and address any concerns you may have. It's important to bring your Hizentra therapy journal, or send infusion records via the MyHizentra™ Infusion Manager app, to share with your healthcare provider.

What are the benefits of a high Ig concentration?

As a 20% IgG therapy, Hizentra has the highest concentration of immunoglobulin available in an Ig treatment, so you can receive the IgG your body needs while infusing a low volume, which potentially results in fewer needle sticks. Hizentra was specifically designed to deliver steady-state IgG levels in half the volume of 10% Ig products,* regardless of which dosing schedule you and your healthcare provider choose.

*Based on an equivalent dose in grams

How long can I store Hizentra at room temperature?

Hizentra can be stored at room temperature (up to 25°C [77°F]) for its entire shelf life, up to 30 months.

Will my insurance cover the cost of Hizentra?

We are working to have Hizentra covered by as many health insurance formularies as possible. We can also help you identify managed care reimbursement opportunities and financial assistance if you're uninsured.

How much does Hizentra cost?

The cost of any treatment, including Hizentra, depends on a number of factors, including insurance status and the insurers' co-pay/coinsurance policy. The actual out-of-pocket cost to a patient will depend on their individual prescription or medical coverage.

For those who cannot afford their treatment, CSL Behring is committed to providing appropriate resources to ensure patients can begin and/or remain on their therapy. These include:

CSL Behring AssuranceSM — The CSL Behring Assurance Program is free and features easy enrollment and participation. The program allows you to earn points for Hizentra that you can use to secure product should you have a lapse in your third-party, private health insurance.

CSL Behring Patient Assistance ProgramSM — The CSL Behring Patient Assistance Program may help if you are uninsured or underinsured, or otherwise can't afford SCIg therapy. If you qualify, you may receive up to a 3-month supply of a SCIg therapy. At the end of 3 months, your eligibility is reevaluated for continued participation. If you have an emergency need for SCIg therapy, it will be addressed under a separate process when the call is received within 24 hours of the emergency.

Hizentra Co-Pay Relief Program – The Hizentra Co-Pay Relief program helps eligible patients afford their therapy by helping with monthly out-of-pocket expenses for Hizentra (up to $5,000 for one year, with no monthly cap).*

To be eligible:

  • Prescription must be for primary immunodeficiency diagnosis
  • Patients must be at least 2 years of age
  • Patient must be receiving Hizentra through a specialty pharmacy or physician office
  • Patient must express financial need
  • Patient must have coverage for the product under a private US insurance plan. Not valid for prescriptions eligible for reimbursement by any federal or state healthcare program, such as Medicare, Medicare advantage plans, Medicaid, PCIP, Champus, TriCare, Veterans Administration (VA), or any other state or federal program
  • Patients whose insurance policy prohibits co-pay assistance are not eligible
  • This program is subject to change or discontinuation by CSL Behring at any time, for any reason, and with or without prior notice
  • Hizentra Co-Pay Relief program is administered by Medmonk Inc.; terms and conditions apply

Simply contact CSL Behring's IgIQ resource hotline at 1-877-355-IGIQ (4447), Monday-Friday, 8 AM to 8 PM ET to confirm eligibility and learn about next steps.

*This program applies to product costs only; however, assistance for infusion-related costs may be available through a non profit patient support organization. Contact IgIQ to learn more.

†Prior to enrolling in this CSL Behring program, participants are responsible for checking with their insurance carrier to confirm that their participation is not inconsistent with their insurance carrier's requirements.

For more information, call the IgIQ Resource Center, CSL Behring's single source for information about immunoglobulin therapies, at 1-877-355-IGIQ (4447), Monday-Friday, 8 AM to 8 PM ET.

Ig Therapy Designed for Freedom
& Flexibility

Hizentra is the first and only 20% SCIg therapy with multiple flexible dosing options, enabling you to infuse at regular intervals from daily up to every 2 weeks, depending on what fits your lifestyle. Hizentra is available in 4 vial sizes, including a 10 g (50 mL) vial.

Important Safety Information

Important Safety Information

WARNING: Thrombosis (blood clotting) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of thrombosis, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor you for signs of thrombosis and hyperviscosity. Always drink sufficient fluids before administration.

Immune Globulin Subcutaneous (Human), Hizentra®, treats various forms of primary immunodeficiency (PI) in patients age 2 and over.

Tell your doctor if you have had a serious reaction to other immune globulin medicines or have been told you also have a deficiency of the immunoglobulin called IgA, as you might not be able to take Hizentra. You should not take Hizentra if you know you have hyperprolinemia (too much proline in your blood).

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.

Tell your doctor about any side effects that concern you. Immediately report symptoms that could indicate a blood clot, including pain and/or swelling of an arm or leg, with warmth over affected area; discoloration in arm or leg; unexplained shortness of breath; chest pain or discomfort that worsens with deep breathing; unexplained rapid pulse; and numbness or weakness on one side of the body. Your doctor will also monitor symptoms that could indicate hemolysis (destruction of red blood cells), and other potentially serious reactions that have been seen with Ig treatment, including aseptic meningitis syndrome (brain swelling); kidney problems; and transfusion-related acute lung injury.

The most common drug-related adverse reactions in the clinical trial for Hizentra were swelling, pain, redness, heat or itching at the site of injection; headache; back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting.

Hizentra is made from components of human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Before being treated with Hizentra, inform your doctor if you are pregnant, nursing or plan to become pregnant. Vaccines (such as measles, mumps and rubella) might not work well if you are using Hizentra. Before receiving any vaccine, tell the healthcare professional you are being treated with Hizentra.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ/09-12-0016k(1) 9/2015